Published in final edited form as:

J Neurovirol. 2012 December ; 18(6): 488–502. doi:10.1007/s13365-012-0128-8.

Translational Spatial Task and its Relationship to HIV-Associated Neurocognitive Disorders and Apolipoprotein E in HIV-Seropositive Women

Diana Morales¹, Summer F. Acevedo^{1,2}, Richard L. Skolasky³, Rosa Hechavarria^{4,5}, Sharon Santiago⁵, Tania De La Torre⁵, Elizabeth Maldonado⁵, and Valerie Wojna^{5,6}

¹Department of Physiology, Pharmacology, and Toxicology, Ponce, Puerto Rico

²Psychology Program, Ponce School of Medicine and Health Sciences, Ponce, Puerto Rico

³Department of Orthopedics, Johns Hopkins University, Baltimore, MD

⁴Department of Physical Medicine and Rehabilitation, University of Puerto Rico, Medical Sciences Campus, San Juan, PR

⁵NeuroAIDS Specialized Neuroscience Research Program, University of Puerto Rico, Medical Sciences Campus, San Juan, PR

⁶Department of Internal Medicine, Neurology Division, University of Puerto Rico, Medical Sciences Campus, San Juan, PR

Abstract

HIV-associated neurocognitive disorders (HAND) continue to be a neurological complication of HIV infection in the era of combined antiretroviral therapy (cART). Hippocampal neurodegeneration and dysfunction occurs as a result of HIV infection, but few studies to date have assessed spatial learning and memory function in patients with HAND. We used the Memory Island (MI) Test to study the effects of HIV infection, *Apolipoprotein E* (*ApoE*) allele status, and CSF ApoE protein levels on spatial learning and memory in our cohort of Hispanic women. The MI Test is a virtual reality-based computer program that tests spatial learning and memory, and was designed to resemble the Morris Water Maze (MWM) test of hippocampal function widely used in rodent studies. In the current study, HIV-seropositive women (n=20) and controls (n=16) were evaluated with neuropsychological (NP) tests, the MI Test, *ApoE*, and CSF ApoE assays. On the MI, the HIV-seropositive group showed significant reduced learning and delayed memory performance compared with HIV-seronegative controls. When stratified by cognitive performance on NP tests, the HIV-seropositive, cognitively impaired group performed worse than HIV-seronegative controls in ability to learn and in the delayed memory trial. Interestingly, differences were observed in the results obtained by the NP tests and the MI Test for $\epsilon 4$ carriers and non-carriers: NP tests showed effects of the $\epsilon 4$ allele in HIV-seronegative women but not HIV-seropositive ones, whereas as the converse was true for the MI Test. Our findings suggest that the MI test is sensitive in detecting spatial deficits in HIV-seropositive women, and that these deficits may arise relatively early in the course of HAND.

Correspondence should be addressed to: Valerie Wojna, MD, Professor of Neurology, Neurology Division, Internal Medicine Department, University of Puerto Rico Medical Sciences Campus, PO Box 365067, San Juan, PR 00936-5067, Tel.: (787) 758-6250; Fax: (787) 777-0078; valerie.wojna1@upr.edu.

Declaration of interest: The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the paper.

Keywords

Spatial Memory; Apolipoprotein E; Cognitive impairment; HIV; women; HAND

Introduction

The prevalence of HIV-associated neurocognitive disorders (HAND) has increased owing to the widespread use of combined antiretroviral treatment (cART) and resulting longer survival of HIV-infected patients (McArthur 2004; Sacktor et al. 2002; Selnes 2005). In the United States, HAND's prevalence among HIV-infected individuals on cART is as high as 50%, and HAND continues to be a significant cause of morbidity in chronically infected patients (Heaton et al. 2011). The majority of these patients suffer from the milder forms of HAND (Antinori et al. 2007; Heaton et al. 2010), which can develop and progress despite adequate viremia control and good cART adherence (Cohen and Gongvatana, 2010; McArthur and Brew, 2010; McArthur et al. 2010; Ragin et al. 2004). HAND is characterized by cognitive impairments and motor dysfunction (Antinori et al. 2007; McArthur and Brew, 2010; Rackstraw, 2011), all of which can persist even with cART treatment (Al-Khindi et al. 2011; McArthur et al. 2010; Rackstraw, 2011). Cognitive deficits in HAND can include alterations in visuospatial learning and memory.

The hippocampus is necessary for the acquisition and retrieval of spatial memory (Burgess, 2008; D'Hooge and De Deyn, 2001; Mishkin and Appenzeller, 1987; Zola et al. 2000). Hippocampal dysfunction in HAND may include atrophy, neuronal cell loss, and functional magnetic resonance imaging (fMRI) abnormalities (Archibald et al. 2004; Castelo et al. 2006; Maki and Martin-Thormeyer, 2009; Sa et al. 2004; Wiley et al. 1998). Studies in rodent models also suggest that HIV infection has multiple deleterious effects on the hippocampus, including synaptic loss and cell death (Kim et al. 2008), impaired neurogenesis (Lee et al. 2011), and disruption of NMDA receptor trafficking (Xu et al. 2011). Despite considerable evidence that HAND affects the hippocampus, only a handful of studies in HIV-infected patients have incorporated tests of spatial memory into their batteries of neurocognitive assessments (Maki and Martin-Thormeyer, 2009; Schouten et al. 2011).

Some studies conducted on HIV-seropositive cohorts (where >70% of all subjects are males) suggest that HIV infection leads to deficits in spatial attention (Covert Orientation of Visual Attention Task [COVAT]) (Maruff et al. 1995; Rohit et al. 2007) and spatial navigation (Money Road Map Test) (Olesen et al. 2007). However, other researchers who used the Rey-Osterrieth Complex Figure Test (RCF) or Visual Design tests (Valcour et al. 2004b; and Krikorian et al. 1990) did not find evidence of impaired visual spatial functioning in subjects with HAND. The variability in these results suggests the need for a more reliable and sensitive tool for testing visuospatial function in HIV-infected patients.

The Morris Water Maze (MWM) has been widely used in rodent models as an instrument with particular sensitivity to the effects of hippocampal lesions (Morris, 1984); reviewed in (D'Hooge and De Deyn, 2001). Table 1 summarizes some of the evidence that spatial learning and memory impairments occur as a consequence of expression of HIV-1 and its related proteins in rodent models using the MWM (D'Hooge et al. 1999; Glowa et al. 1992; Griffin et al. 2004; Tang et al. 2009; Zink et al. 2002). Rodent HIV models also tend to show impairment in the Barnes maze (Sanchez-Alavez et al. 2000), radial arm maze (Li et al. 2004), and radial arm water maze (Keblesh et al. 2009) (Table 1). However, it has been questioned how well the MWM translates to learning and memory tests typically used in humans. Therefore, we sought to determine if there are spatial learning and/or memory

impairments in HIV-seropositive individuals using a task that may more faithfully bridge animal and human studies, the “Memory Island” (MI) test. The MI, described previously in Rizk-Jackson et al. (2006), is a virtual reality-based spatial learning and memory task developed for use in humans based on the MWM. The MI is a virtual island on which participants are asked to navigate to four different targets marked with visible indicators, each of which is located in a different quadrant of the island (visible trial). Then, in subsequent trials, they return to the island and find the targets again, this time without visible indicators (hidden trials). MI has been successfully used in a wide range of age groups (6-99 years) and shows sensitivity to gender, age, and genetic factors (such as *ApoE* genotype) similar to that seen with the MWM in animal (Acevedo et al. 2010; Raber, 2008; Raber et al. 2000; Rizk-Jackson et al. 2006).

A second question we addressed using the MI concerned the impact of *Apolipoprotein E* (*ApoE*) allele status on cognitive performance in HIV-infected individuals. ApoE proteins play a central role in the metabolism and transport of lipoproteins and cholesterol, and also appear to be important modulators of neuronal development, plasticity, and recovery from injury (Herz and Beffert, 2000; Vance and Hayashi, 2010). Distinct alleles ($\epsilon 2$, $\epsilon 3$, and $\epsilon 4$) encode human isoforms, and have been studied as risk factors for many different conditions. For example, compared with $\epsilon 2$ and $\epsilon 3$, the $\epsilon 4$ allele confers increased risk of age-related cognitive impairment and the development of Alzheimer’s disease (AD), especially in women (Bu, 2009; Raber, 2008). The $\epsilon 4$ allele has also been linked to worse cognitive outcomes in various conditions that cause brain injury, such as cardiac bypass surgery (Newman et al. 1995) and multiple sclerosis (Shi et al. 2008). The $\epsilon 4$ allele may also contribute to the development of HAND. Possession of the $\epsilon 4$ allele has been linked to accelerated progression of HIV infection and a higher incidence of HIV-associated dementia (Corder et al. 1998; Dunlop et al. 1997; Valcour et al. 2004b). In addition, a recent study in HIV-seropositive males showed that higher levels of CSF ApoE protein were correlated with better cognitive performance in $\epsilon 2$ or $\epsilon 3$ carriers, but worse cognitive performance in $\epsilon 4$ carriers (Andres et al. 2011). Thus, $\epsilon 4$ allele may interact with HIV infection to increase risk of HAND, particularly in women. We therefore examined the potential associations of $\epsilon 4$ status and CSF levels of ApoE protein with cognitive impairment in women with HIV infection.

Methods

Cohort description

This study is nested in the approved Hispanic-Latino Longitudinal Cohort of HIV-seropositive Women as part of the NeuroAIDS Specialized Neuroscience Research Program (SNRP) at the University of Puerto Rico (UPR), Medical Science Campus (MSC) (HLLC) with appropriate internal review (IRB) approval. This is a unique cohort of Hispanic HIV-seropositive women characterized with respect to their viral immune profiles, neurological function, and neuropsychological performance (Luo et al. 2003; Wojna et al. 2006). All seropositive women were screened at their primary HIV clinics at the Puerto Rico Medical Center (Clinica de Enfermedades Transmitidas Sexualmente [CLETS] and Longitudinal Materno-Infant Clinic [CEMI]) and community-based organizations. This study used a convenient sample of 20 HIV-seropositive and 16 HIV-seronegative women from the HLLC and seronegative controls consecutively recruited as they were evaluated in the cohort (described previously in Wojna et al. 2006). HIV-seronegative (control) CSF samples were provided by Dr. Carlos Pardo at Johns Hopkins University, Baltimore, MD (JHU), and obtained from patients examined by a neurologist for non-HIV related conditions (3/6 normal participants [no neurological disorders], 2/6 Multiple Sclerosis, 1/6 with Common Variable Immune Deficiency) after obtaining appropriate consent from JHU IRB as banked samples for biological testing.

Neurocognitive Assessments

The battery of neurocognitive assessments has been previously described (Luo et al. 2003; Velázquez et al. 2009; Wojna et al. 2006; Wojna et al. 2007). The assessments included five different cognitive domains (tests): Frontal Executive Function (Stroop Color Word Test, Trail Making B [TMB]), Psychomotor Speed (Symbol Digit Modality Test [SDMT]), Visual Reaction Time non-dominant hand, Auditory Reaction Time non-dominant hand), Verbal Memory (Rey Auditory Learning Test [RVALT]; Trial 5, Memory Recall, Delayed Memory), and Motor Speed (Trail Making A [TMA], Grooved Pegboard [non-dominant and dominant hand]). All assessments were conducted in Spanish. Individual z-scores were calculated using a reference group of 35 HIV-seronegative females. No differences were seen between the reference group and HIV-seronegative or HIV-seropositive in regard to age, education, vocabulary, reading, and annual income ($p>0.05$).

HIV cognitive impairment determination

Cognitive status was determined using the American Academy of Neurology HIV dementia criteria (AAN criteria) (American Academy of Neurology AIDS Task Force, 1991; American Academy of Neurology AIDS Task Force, 1996), modified to include criteria for asymptomatic cognitive impairment. Asymptomatic cognitively impaired patients are defined as those who have abnormal neuropsychological test results (1 SD in two or more tests, or 2 SD in one or more tests, below the normal control group), but who do not exhibit current neurological deficits during medical and neuropsychological examinations and who report no functional/emotional disturbances in quality of life questionnaires (Wojna et al. 2006). For the purposes of this study, we combined participants with normal cognitive function ($n=8$) and those with asymptomatic impairment (ANI, $n=3$) as the HIV-seropositive normal cognition group and minor cognitive motor disturbance (MCMD, $n=4$) and HIV-associated dementia (HAD, $n=5$) in the impaired group.

Memory Island (MI) test

All women were asked to enter a virtual environment designed to test spatial learning and memory (Rizk-Jackson et al. 2006), which consisted of an island with trees, house, hills, grass, sidewalks, and buildings. Women navigated through the environment using a joystick, while listening to sounds such as birds singing and water flowing through headphones that simulated movement through the environment. During training sessions (duration ≈ 10 minutes), the women were free to explore the environment to find (one at a time) four different targets marked by large, brightly colored flags ("*visible trials*"). The women were then asked in four consecutive trials (each restarting in the middle of the island) to navigate the island using spatial cues to locate the each of the four targets, but without flag locators ("*hidden trials*"). During each trial, after two minutes the subjects were given an arrow at the top of the screen to help guide them to the target. In the hidden trials, after a 15 minute delay the women were asked to find the target location with 30 seconds remaining to perform the task. The environment is located on a quadrant-based coordinate system, so that distance and latency to target can be measured. Cumulative distance to target was calculated by determining the distance between the participant and the target every two seconds. Percentage of successful trials was determined as the percent in which the participant was able to find the target without the aid of the arrow. For the probe determination, we measured time spent in each of the four quadrants. The MI test was conducted with a culturally appropriate Spanish script and visual word prompts. Copyright permission was obtained from Jacob Raber, Ph.D., Professor in the Department of Neurology at Oregon Health and Science University for the use of this program.

ApoE Genotyping

Blood was collected from seropositive participants and purified as previously described (Toro-Nieves et al. 2009; Velázquez et al. 2009). Saliva was collected from the seronegative participants using Oragene DNA kits (DNA Genotek, Ottawa, Canada) and shipped or taken to Dr. Summer Acevedo's laboratory at the Ponce School of Medicine for purification. Polymerase chain reactions (PCRs) were performed using 5'-TCCAAGGAGCTGCAGGCGGCGCA-3' (upstream) and 5'-ACAGAATTGCCCCGGCCTGGTACACTGCCA-3' (downstream) primers, then digested overnight at 37°C with CfoI. Products were run on 4% agarose gels with the bands categorized by size used to identify genotypes (Wenham et al. 1991).

ELISA for total ApoE levels

ApoE levels were measured in previously frozen CSF samples of HIV-seronegatives from JHU and HIV-seropositive women samples from the HLLC using an ELISA for total human ApoE (MABTECH, 3814 West Street, Mariemount, OH, USA), based on a quantitative sandwich method in a 96 well plate. ApoE assays were performed and analyzed using manufacturer's protocol. Protein concentrations in diluted CSF samples were within the linear range of the standard curve generated for each assay, and triplicate measurements were obtained for each sample (3μL). A standard solution was used to produce a standard curve. A Bradford protein analysis was completed for each sample to calculate total CSF protein levels and adjustments were made to values calculated from the standard curve to equalize total protein levels produced final total ApoE protein levels (μg/mL) used for comparisons between groups.

Data Analysis

All data was collected using standard data forms and entered into a Microsoft Excel spreadsheet for analysis using SPSS software, version 17. The assumption of normal distribution was tested for continuous variables (e.g. spatial learning score) using Shapiro-Wilk test. Student's T-tests were conducted between genotypes (non-*ε4*, *ε4*) or HIV-status (HIV-seronegative or HIV-seropositive) for neurocognitive performance and biological measures. Analysis of Variance (ANOVA) were used in the comparison of HIV-seronegative subjects to HIV-seropositive subjects stratified into two cognitive performance groups (normal and impaired), with subsequent Tukey's post-hoc to distinguish difference in subgroups. Values are reported as F value (degrees of freedom) and *p* value. For the MI test, Repeated Measure ANOVAs were conducted on measures of velocity and performance (latency to target) across trials during visible and hidden trials. For the probe determination, the Wilcoxon Signed Ranks Test was used to test the median differences between the percent time spent in the target quadrant and the percent spent all other quadrants. For all analyses, *p* < 0.05 was considered statistically significant. All graphs were preformed using Prism.

Results

Subject Demographics

HIV-seropositive women and seronegative controls were similar in age and education (Puerto Rican and Spanish speaking) (Table 2, 3). When HIV-seropositive women were stratified by cognitive performance into groups with normal cognition and impaired cognition (see Methods), Student's *t*-test indicated no differences between the groups with regard to plasma ribonucleic acid (RNA) HIV viral load, cerebral spinal fluid (CSF) HIV RNA viral load, type of anti-viral treatment or protease inhibitor treatment, or Central Nervous System penetration effect of the cART (CPE) (Letendre et al. 2010) (Table 2). For

the neuropsychological assessments, HIV-seronegative controls and HIV-seropositive women stratified by cognitive impairment showed no significant differences in reading and vocabulary status, and Beck's Depression Index (Table 2).

Neuropsychological Assessments

Significant differences in performance on NP tests were seen between controls and HIV-seropositive women stratified by cognitive performance (normal vs. impaired) using ANOVA (Table 3). Overall neuropsychological testing z-scores (NPZ) and performance in the frontal executive, psychomotor speed, and motor speed cognitive domains were significantly different among groups (Table 3, $p < 0.05$). Tukey's post-hoc analysis indicated differences between the HIV-seronegative and HIV-seropositive impaired group for the NPZ ($p < 0.04$), psychomotor speed ($p < 0.02$) and motor speed cognitive domains ($p < 0.03$), and individual scores on the Symbol Digit Modalities Test ($p < 0.03$). These findings are consistent with those of other studies using different samples from this same cohort (Wojna et al. 2006; Wojna et al. 2007a; Wojna et al. 2007b).

HIV and Memory Island (MI) test

In order to identify possible group differences in the spatial learning (visible target) and immediate memory (hidden target) trials of the MI, we first analyzed differences between HIV-seronegative and HIV-seropositive women. Differences were seen between these groups with respect to *velocity* (virtual units/sec) in the visible trials and hidden trials ($F(34) = 5.70$, $p < 0.03$ and $F(34) = 6.01$, $p < 0.02$, Figure 1A), where the seropositive group navigated more slowly than the seronegative group. However, when the HIV-seropositive group was stratified by cognitive performance using Repeated Measures ANOVAs, the HIV-seropositive impaired group showed a trend towards reduced velocities in both the visible trials ($F(33) = 2.80$, $p = 0.08$) and the hidden trials ($F(33) = 2.98$, $p = 0.07$, Figure 1A). Overall, the HIV-seropositive women navigated more slowly, with the seropositive impaired group showing a trend toward being the slowest group.

Regarding time required to find the target, *latency*, a significant difference was observed across HIV serostatus, with the seropositive group having a higher *latency* ($F(34) = 5.70$, $p < 0.03$, Figure 1B). When stratified by cognitive performance, a significant difference in *average latency* in visible trials was observed between groups ($F(33) = 5.42$, $p < 0.01$, Figure 1B), where a Tukey's post-hoc test ($p < 0.01$) indicated impaired performance in the seropositive women compared to seronegative controls. The *average latency* in hidden trial showed a similar trend, although it was not statistically significant.

With regard to success in finding the target in the first 2 minutes, *cumulative distance to target*, a Repeated Measures ANOVA indicated differences between women of the seropositive group and those from the seronegative group during visible trials ($F(34) = 5.80$; $p < 0.02$, Figure 1C). Stratification by cognitive performance of the HIV-seropositive group compared to seronegatives indicate difference in both visible ($F(33) = 5.66$; $p < 0.01$, Figure 1C) and hidden ($F(33) = 5.66$; $p < 0.01$, Figure 1C) trials with Tukey's post-hoc, suggesting the HIV-seropositive cognitively impaired group had worse performance.

For all groups (both before and after stratification) there was an improvement in *velocity*, *latency*, and *cumulative distance to target* overall performance within trials, both visible and hidden ($p < 0.01$, data not shown).

An ANOVA between the seropositive and the seronegative groups in the visible *percentage of successful trials*, suggested a difference between groups during the visible trial ($F(35) = 3.76$ $p < 0.04$, Figure 1D). In addition, there were differences between the seronegative group and the seropositive women stratified by cognitive status groups in the percentage of

successful visible trials ($F(35) = 4.77, p < 0.04$, Figure 1D), with Tukey's post-hoc test indicating the seropositive impaired group had the lowest success compared to seronegative subjects.

Overall our results suggest that the HIV-seropositive impaired group had difficulties in learning in the MI test compared to the HIV-seropositive group with normal cognition and HIV-seronegative controls.

After 15 minutes, the subjects were given 30 seconds to again find the same hidden target (*probe trial*). By the Wilcoxon signed-rank test, the HIV-seronegative participants had a higher *percent time in quadrant*, in the target quadrant during the delayed probe trial ($p < 0.01$, target vs. all other quadrants, Figure 1E), with 93.7% showing preference (>51% time) for the target quadrant. However, the HIV-seropositive subjects did not spend more time in the target quadrant than they did in the adjacent quadrant to the right of the intended target (Figure 1E). When the seropositive participants were stratified by cognitive performance, the seropositive normal group spent more time in the target quadrant than they did in the left or opposite quadrant, with a small difference ($p = 0.07$) in the time spent in the right quadrant (Figure 1E). The seropositive impaired women showed equal preference for the target quadrant and the right quadrant where 63% showed preference for the target (>51% time spent in target quadrant, Figure 1E).

In summary, HIV-seropositive women with a cognitive impairment displayed spatial memory impairments in the virtual reality MI task.

Correlations between Memory Island (MI) test and Other Neuropsychological Tests Spearman's correlation analysis including both seropositive and seronegative women demonstrated a strong correlation between performance in the MI task and other cognitive measures (Table 4). There was a significant correlation between performance on the visible latency trial (i.e., the learning portion of MI) and hidden latency trial (i.e., the immediate memory portion of MI) with overall NPZ scores (p values of 0.02 and 0.01 respectively), as indicated in Table 4. Performance on the learning and immediate memory portions of the MI task in particular correlated ($p < 0.05$) to psychomotor speed cognitive domain, with strong correlations with the Trail Making B test and the Symbol Digit Modalities Test. The immediate memory portion of the task also correlated with frontal executive cognitive domain ($p < 0.04$). These correlations mirror differences between neuropsychological test performance in HIV-seronegative and HIV-seropositive subjects, stratified by cognitive performance. In the MI paradigm, the probe trial assesses delayed memory; this kind of memory correlated with the psychomotor speed subtest, mostly due to the measures the auditory reaction time (RT) of the non-dominant hand performance.

ApoE Study-Population Characteristics

HIV-seronegative and-seropositive women were matched by age and other factors (Puerto Rican, Spanish-speaking, economic status) and did not differ with respect to frequency of non- $\epsilon 4$ ($\epsilon 3/\epsilon 3$) and the heterozygous $\epsilon 3/\epsilon 4$ genotypes. In the seropositive group, Student's t -test indicated no differences between $\epsilon 4$ carrier groups with regard to RNA viral load, CSF RNA viral load, CD4 T-cell counts, CD4 nadir, use of cART or protease inhibitor medications, CPE, BDI scores, or cognitive performance (Table 5). Due to the limited number of participants, stratification by cognitive performance (normal or impaired) was not possible.

ApoE Genotype and Neurocognition

A Student's t -test analysis of neurocognitive assessments showed that in the HIV-seronegative group, $\epsilon 4$ carriers scored lower in NPZ, in frontal executive cognitive domain

(driven by the performance of the Stroop Color-Word Test), and in verbal memory cognitive domain (subtest RAVLT memory recall [trial 5]) (Table 5). Among the HIV-seropositive women, no differences were seen between the different allele carrier groups for any of the standardized neurocognitive test measures (Table 5). This finding suggests that while $\epsilon 4$ status impacts cognitive performance in healthy individuals, it may not have this effect in our sample of HIV-seropositive women (at least the cognitive performance measures used and our sample size).

ApoE Genotype and MI

Due to sample number with respect to genotype for all MI analysis were conducted using Repeated Measures ANOVA with genotype (non- $\epsilon 4$ vs. $\epsilon 4$) as the between subjects and trial as within variable for each HIV status groups unless otherwise indicated. Among the genotypes there was no differences in average *velocity* (virtual units/sec) in either the visible or the hidden trials for either HIV status groups (Figure 2A).

There was a trend towards a difference between non- $\epsilon 4$ and $\epsilon 4$ carriers in the seronegative group across the visible latency trials with regard to the time it took them to arrive at the target, *latency* ($F(14) = 3.48$, $p=0.07$, Figure 2B). In the seropositive group, there was a significant difference between $\epsilon 4$ carrier groups in visible latency trial ($F(18) = 4.97$, $p<0.04$, Figure 2B). This finding suggests a potential interacting effect between being an $\epsilon 4$ carrier and being HIV-seropositive in relation to spatial learning assessed by MI. Although a similar trend was observed in the *latency* during the hidden trials, no significant differences were found based on genotype (Figure 2B).

No significant differences between carrier groups for either the seropositive or seronegative women were found in either visible or hidden trials during the first two minutes measured by *cumulative distance to target* (Figure 2C). The performance of all groups improved across trials during visible and hidden trials for *velocity*, *latency*, and *cumulative distance to target* ($p<0.01$, data not shown).

Student's *t*-test indicated an overall difference in *percentage of successful hidden trials* between non- $\epsilon 4$ and $\epsilon 4$ carriers in the seropositive group only ($p<0.05$, Figure 2D). Fewer HIV-seropositive $\epsilon 4$ carriers women were able to find the target within the first two minutes.

Overall, there is evidence that the $\epsilon 4$ carrier seropositive groups displayed the worst performance in MI for both visible and hidden trials, pointing to a potential effect of genotype on visuospatial memory that must be considered in future studies.

Lastly, after a 15-minute wait, subjects were asked to again find the same hidden target during the probe trial. Seronegative participants of both genotypes spent more time in the target quadrant, *percent time in quadrant*, during the delayed probe trial ($p<0.01$ target vs. all other quadrants, Figure 2E), with 80% and 100% showing a preference ($>51\%$ time) for the target quadrant. These results are similar to those reported in a previous study of healthy adults (Rizk-Jackson *et al.* 2008). HIV-seropositive non- $\epsilon 4$ carriers also spent more time in the target quadrant compared to all other quadrants, with a 78.6% preference ($p<0.05$, Figure 2E). However, seropositive $\epsilon 4$ carriers spent equal amounts of time in the target quadrant and the opposite quadrant, having only a 40% target quadrant preference (Figure 2E). Thus, for seropositive women, being an $\epsilon 4$ carrier may be associated with an increased risk of impairment in delayed visual spatial memory.

CSF ApoE protein levels and neurocognition

No differences in CSF ApoE protein levels were observed between HIV-seropositive women based on HAND status (Table 2) or $\epsilon 4$ carrier status (Table 5). However, according

to Student's T-test ApoE protein levels were lower in seropositive women ($5.0\mu\text{g/mL} \pm 0.8$; $n=20$), compared to seronegative samples ($9.3\mu\text{g/mL} \pm 2.4$; $n=6$) provided by the Johns Hopkins University CSF repository ($p<0.05$). No correlations were observed between protein levels and neurocognitive test measures, MI performance, or other biological measures.

Discussion

HIV has detrimental effects on cognition even in otherwise asymptomatic individuals, and may affect spatial navigation functions (Olesen et al. 2007; Heaton et al. 2011). We assessed spatial learning and memory performance in HIV-seropositive women using the virtual reality-based MI task. The MI test is modeled after the MWM, which is widely used to evaluate spatial learning and memory in rodent models, and is unique in that it is performed in a naturalistic human environment. Our studies with the MI task revealed reduced average velocity for the HIV-seropositive group compared to the seronegative group during the visual but not the hidden trials. When the HIV-seropositive patients were stratified by cognitive function, the seropositive impaired group showed worse performance than the control, seronegative group that suggested difficulty in learning how to navigate to the targets. These results are consistent with those from Olesen et al. (2007), who observed that HIV-seropositive participants showed impaired performance on standard clinical NP tests of spatial learning function. The fact that no differences were found when comparing HIV-seropositive normal and impaired women in MI performance, could reflect the relatively small sample sizes, or the fact that three out of the eleven women included in the HIV-seropositive "normal" group had asymptomatic cognitive impairment. Alternatively, it is possible that spatial learning is affected early in the disease, and that the HIV-positive women classified as "normal" in the NP tests were actually beginning to have spatial learning deficits to which the MI test was sensitive. To further explore these issues, we currently have an ongoing study to extend our analyses with larger sample sizes and validate them with neuroimaging studies.

In our sample, we observed that the HIV-seropositive, cognitively impaired women displayed impairments in both immediate and delayed memory on the MI task. These findings are consistent with studies in HIV-1 mouse models (Table 1). Investigators have suggested that the cognitive deficits observed in these studies are associated with significant increases in astrogliosis and microgliosis, a possible explanation for our findings (Griffin et al. 2004). Additionally, there is evidence in Tat-mice (Fitting et al. 2008; personal communication) or with gp120 treatment (Sanchez-Alavez et al. 2000) there are impairments in the induction and maintenance of long-term potentiation (LTP) of the hippocampus interfering with spatial learning and memory (Table 1).

We observed strong associations between MI task performance measures and cognitive measures, as well as between the *visible trial* (learning portion) and *hidden trial* (immediate memory) portions of the MI task, with the overall NPZ score. The immediate memory portion of the MI task in particular correlated with overall psychomotor speed, with strong correlations with scores on the Trail Making B and Symbol Digit Modality tests. These correlations support the idea that immediate memory performance on the MI task may be dependent on psychomotor speed, although a component of attention can not be fully ruled out. Immediate memory portion of the task also correlated with subtests for frontal executive function and verbal memory cognitive domains. This data is consistent with earlier studies in Caucasians and other populations showing that MI performance is dependent on psychomotor speed, executive function, and memory function (Ayala-Feliciano et al. 2011; Piper et al. 2010).

We also examined the potential impact of $\epsilon 4$ allele status on cognition in both HIV-seropositive and seronegative women. We found that the $\epsilon 4$ allele was associated with impaired performance on the NP test battery in the control, seronegative women. In the MI task, we observed a trend in the seronegative group towards a difference between non- $\epsilon 4$ and $\epsilon 4$ carriers across *visible trials in latency* to the target. Lack of *ApoE* genotype effects on cognitive performance in seronegative women is consistent with other studies with in both Caucasian and Hispanic women of similar age (Acevedo's unpublished data).

In contrast, in the HIV-seropositive group, $\epsilon 4$ carriers and non-carriers showed significant differences in their performance in certain MI test measures. In the seropositive group, $\epsilon 4$ carriers showed increased latency to target in the visible trials, and also performed worse in the immediate memory and delayed memory portions of the task. These data suggest that for HIV-seropositive women, being an $\epsilon 4$ carrier may be associated with increased risk of impairment in *delayed visual spatial memory*, supporting the idea that HIV infection and the $\epsilon 4$ genotype both have an effect on neurocognitive performance in HIV-seropositive patients. These findings are also consistent with prior studies reporting that the $\epsilon 4$ allele is associated with accelerated progression of HIV disease (Burt et al. 2008) and an increased risk of developing HAND (Corder et al. 1998; Valcour et al. 2004b). In contrast, other studies did not find an association between the $\epsilon 4$ carriers and increased risk of cognitive deficits in HIV subjects (Joska et al. 2010; Pomara et al. 2008). There are many variable, including differences in age, gender, race/ethnicity, HIV viral strain (Joska et al. 2010), and cART, that may contribute to the differences observed between studies.

Higher levels of CSF ApoE protein have been correlated with worse cognitive performance in Alzheimer's disease patients (Fukuyama et al. 2000), and in HIV-seropositive males carrying the $\epsilon 4$ allele (Andres et al. 2011). However, we observed no correlation between CSF ApoE levels and cognitive performance in our study. One possible explanation for our different findings may be that our HIV-seropositive sample consists entirely of women, whereas the sample in the Andres *et al.* study was predominately male (Andres *et al.*, 2011). However, our results agreed with the Andres *et al.* (2011) study in that both studies observed that CSF ApoE protein levels are lower in HIV patients when compared to controls. Among our HIV-seropositive women, $\epsilon 4$ and non- $\epsilon 4$ carriers showed no differences in CSF ApoE protein levels, consistent with a previous study done in males (Andres *et al.*, 2011). There are two possible explanations for our results: (1) that neurocognitive performance in HIV-seropositive women is not associated with changes in CSF ApoE protein levels, or (2) that our sample size is a limiting factor in detecting correlations with neurocognitive performance; both alternatives will be examined in the future.

There are a few limitations to the current study. Our sample size was small, and the HIV-seropositive subgroups were smaller after stratification by level of cognitive impairment. However, our results are consistent with those of certain previous studies in showing (1) impairment of spatial learning and memory in seropositive women using a standardized pen and pencil assessment and (2) an association of the $\epsilon 4$ allele with worse cognitive performance in seropositive individuals. In addition, this is the first study to examine the use of a translational paradigm, the MI test, to assess cognitive impairment in HIV-seropositive individuals. Our results support the use of the MI test to study spatial learning and memory deficits in HAND, and to assess potential therapeutics for these deficits. Finally, our study participants were relatively young (mean age <42 years) and were all women. Given prior data implicating interactions between $\epsilon 4$ genotype with age (Alexander et al. 2007; Mondadori et al. 2007; Valcour et al. 2004a) and gender (Payami et al. 1996), it will be of interest to include older individuals and men in future studies.

Acknowledgments

I would like to thank Madeline Collazo for helping with genotyping. The study was funded by National Center for Research Resources (NCRR) grant 1U54RR026139-01A1 and the National Institute on Minority Health and Health Disparities 8U54MD007587 to the University of Puerto Rico-Medical Science Campus, and National Institute of Mental Health (NIMH) Center for Novel Therapeutics of HIV-associated Cognitive Disorders Pilot Project Grant G12 RR003050 to the John Hopkins University. The study was partially supported by National Institute of Neurological Disorders and Stroke (NINDS) grants S11NS46278 and U54NS43011 (SNRP). The content of this publication is solely the responsibility of the authors and does not necessarily represent the official views of NCRR, NIMHD, NIMH, or NINDS. Thanks to Dr. Carlos Pardo at John Hopkins University for the control CSF samples. Thanks to Dr. Jacob Raber at Oregon Health & Science University for permission to use the Memory Island and serving as an excellent mentor. We also appreciate the contribution from Dr. Raul Mayo whom conducted neuropsychological testing of cohort participants and Dr. Avindra Nath for his contribution in the development of the cohort and continuous collaboration with the SNRP. We acknowledge the support of Tirtsia Porrata-Doria and the Molecular Biology Core Lab, (Grant RR003050). Special thanks go to Robert Ritchie of the RCMI Publications Office (G12 RR003050).

References

- Acevedo SF, Piper BJ, Craytor MJ, Benice TS, Raber J. Apolipoprotein E4 and sex affect neurobehavioral performance in primary school children. *Pediatr Res*. 2010; 67:293–299. [PubMed: 19952867]
- Alexander DM, Williams LM, Gatt JM, Dobson-Stone C, Kuan SA, Todd EG, Schofield PR, Cooper NJ, Gordon E. The contribution of apolipoprotein E alleles on cognitive performance and dynamic neural activity over six decades. *Biol Psychol*. 2007; 75:229–238. [PubMed: 17433528]
- American Academy of Neurology AIDS Task Force; Report of a Working Group of the American Academy of Neurology AIDS Task Force. Nomenclature and research case definitions for neurologic manifestations of human immunodeficiency virus-type 1 (HIV-1) infection. *Neurology*. 1991; 41:778–785. [PubMed: 2046917]
- American Academy of Neurology AIDS Task Force; The Dana Consortium on Therapy for HIV Dementia and Related Cognitive Disorders. Clinical confirmation of the American Academy of Neurology algorithm for HIV-1-associated cognitive/motor disorder. *Neurology*. 1996; 47:1247–1253. [PubMed: 8909438]
- Andres MA, Feger U, Nath A, Munsaka S, Jiang CS, Chang L. APOE epsilon 4 allele and CSF APOE on cognition in HIV-infected subjects. *J Neuroimmune Pharmacol*. 2011; 6:389–398. [PubMed: 21184197]
- Antinori A, Arendt G, Becker JT, Brew BJ, Byrd DA, Cherner M, Clifford DB, Cinque P, Epstein LG, Goodkin K, Gisslen M, Grant I, Heaton RK, Joseph J, Marder K, Marra CM, McArthur JC, Nunn M, Price RW, Pulliam L, Robertson KR, Sacktor N, Valcour V, Wojna VE. Updated research nosology for HIV-associated neurocognitive disorders. *Neurology*. 2007; 69:1789–1799. [PubMed: 17914061]
- Archibald SL, Masliah E, Fennema-Notestine C, Marcotte TD, Ellis RJ, McCutchan JA, Heaton RK, Grant I, Mallory M, Miller A, Jernigan TL. Correlation of in vivo neuroimaging abnormalities with postmortem human immunodeficiency virus encephalitis and dendritic loss. *Arch Neurol*. 2004; 61:369–376. [PubMed: 15023814]
- Ayala-Feliciano M, Pons-Valerio JJ, Pons-Madera J, Acevedo SF. The Relationship between visuospatial memory and coping strategies in breast cancer survivors. *Breast Can Basic Clin Res*. 2011; 5:117–130.
- Bu G. Apolipoprotein E and its receptors in Alzheimer's disease: pathways, pathogenesis and therapy. *Nat Rev Neurosci*. 2009; 10:333–344. [PubMed: 19339974]
- Burgess N. Spatial cognition and the brain. *Ann N Y Acad Sci*. 2008; 1124:77–97. [PubMed: 18400925]
- Burt TD, Agan BK, Marconi VC, He W, Kulkarni H, Mold JE, Cavrois M, Huang Y, Mahley RW, Dolan MJ, McCune JM, Ahuja SK. Apolipoprotein (apo) E4 enhances HIV-1 cell entry in vitro, and the APOE epsilon4/epsilon4 genotype accelerates HIV disease progression. *Proc Natl Acad Sci U S A*. 2008; 105:8718–8723. [PubMed: 18562290]

- Castelo JM, Sherman SJ, Courtney MG, Melrose RJ, Stern CE. Altered hippocampal-prefrontal activation in HIV patients during episodic memory encoding. *Neurology*. 2006; 66:1688–1695. [PubMed: 16769942]
- Cohen RA, Gongvatana A. The persistence of HIV-associated neurocognitive dysfunction and the effects of comorbidities. *Neurology*. 2010; 75:2052–2053. [PubMed: 21135377]
- Corder EH, Robertson K, Lannfelt L, Bogdanovic N, Eggertsen G, Wilkins J, Hall C. HIV-infected subjects with the E4 allele for APOE have excess dementia and peripheral neuropathy. *Nat Med*. 1998; 4:1182–1184. [PubMed: 9771753]
- D’Hooge R, De Deyn PP. Applications of the Morris water maze in the study of learning and memory. *Brain Res Brain Res Rev*. 2001; 36:60–90. [PubMed: 11516773]
- D’Hooge R, Franck F, Mucke L, De Deyn PP. Age-related behavioural deficits in transgenic mice expressing the HIV-1 coat protein gp120. *Eur J Neurosci*. 1999; 11:4398–4402. [PubMed: 10594667]
- Dunlop O, Goplen AK, Liestol K, Myrvang B, Rootwelt H, Christophersen B, Kvittingen EA, Maehlen J. HIV dementia and apolipoprotein E. *Acta Neurol Scand*. 1997; 95:315–318. [PubMed: 9188909]
- Fitting S, Booze RM, Mactutus CF. Neonatal intrahippocampal injection of the HIV-1 proteins gp120 and Tat: differential effects on behavior and the relationship to stereological hippocampal measures. *Brain Res*. 2008; 1232:139–154. [PubMed: 18674522]
- Fukuyama R, Mizuno T, Mori S, Yanagisawa K, Nakajima K, Fushiki S. Age-dependent decline in the apolipoprotein E level in cerebrospinal fluid from control subjects and its increase in cerebrospinal fluid from patients with Alzheimer’s disease. *Eur Neurol*. 2000; 43:161–169. [PubMed: 10765057]
- Glowa JR, Panlilio LV, Brenneman DE, Gozes I, Fridkin M, Hill JM. Learning impairment following intracerebral administration of the HIV envelope protein gp120 or a VIP antagonist. *Brain Res*. 1992; 570:49–53. [PubMed: 1617429]
- Griffin WC, Middaugh D, Cook JE, Tyor WR. The severe combined immunodeficient (SCID) mouse model of human immunodeficiency virus encephalitis: deficits in cognitive function. *J Neurovirol*. 2004; 10:109–115. [PubMed: 15204929]
- Heaton RK, Clifford DB, Franklin DR Jr, Woods SP, Ake C, Vaida F, Ellis RJ, Letendre SL, Marcotte TD, Atkinson JH, Rivera-Mindt M, Vigil OR, Taylor MJ, Collier AC, Marra CM, Gelman BB, McArthur JC, Morgello S, Simpson DM, McCutchan JA, Abramson I, Gamst A, Fennema-Notestine C, Jernigan TL, Wong J, Grant I. HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study. *Neurology*. 2010; 75:2087–2096. [PubMed: 21135382]
- Herz J, Beffert U. Apolipoprotein E receptors: linking brain development and Alzheimer’s disease. *Nat Rev Neurosci*. 2000; 1:51–58. [PubMed: 11252768]
- Joska JA, Combrinck M, Valcour VG, Hoare J, Leisegang F, Mahne AC, Myer L, Stein DJ. Association between apolipoprotein E4 genotype and human immunodeficiency virus-associated dementia in younger adults starting antiretroviral therapy in South Africa. *J Neurovirol*. 2010; 16:377–383. [PubMed: 20825268]
- Keblesh JP, Dou H, Gendelman HE, Xiong H. 4-Aminopyridine improves spatial memory in a murine model of HIV-1 encephalitis. *J Neuroimmune Pharmacol*. 2009; 4:317–327. [PubMed: 19462247]
- Kim HJ, Martemyanov KA, Thayer SA. Human immunodeficiency virus protein Tat induces synapse loss via a reversible process that is distinct from cell death. *J Neurosci*. 2008; 28:12604–12613. [PubMed: 19036954]
- Krikorian R, Wrobel AJ, Meinecke C, Liang WM, Kay J. Cognitive deficits associated with human immunodeficiency virus encephalopathy. *J Neuropsychiatry Clin Neurosci*. 1990; 2:256–260. [PubMed: 2136083]
- Lashomb AL, Vigorito M, Chang SL. Further characterization of the spatial learning deficit in the human immunodeficiency virus-1 transgenic rat. *J Neurovirol*. 2009; 15:14–24. [PubMed: 19085205]
- Lee MH, Wang T, Jang MH, Steiner J, Haughey N, Ming GL, Song H, Nath A, Venkatesan A. Rescue of adult hippocampal neurogenesis in a mouse model of HIV neurologic disease. *Neurobiol Dis*. 2011; 41:678–687. [PubMed: 21146610]

- Letendre SL, Ellis RJ, Ances BM, McCutchan JA. Neurologic complications of HIV disease and their treatment. *Top HIV Med.* 2010; 18:45–55. [PubMed: 20516524]
- Li ST, Matsushita M, Moriwaki A, Saheki Y, Lu YF, Tomizawa K, Wu HY, Terada H, Matsui H. HIV-1 Tat inhibits long-term potentiation and attenuates spatial learning [corrected]. *Ann Neurol.* 2004; 55:362–371. [PubMed: 14991814]
- Luo X, Carlson KA, Wojna V, Mayo R, Biskup TM, Stoner J, Anderson J, Gendelman HE, Melendez LM. Macrophage proteomic fingerprinting predicts HIV-1-associated cognitive impairment. *Neurology.* 2003; 60:1931–1937. [PubMed: 12821735]
- Maki PM, Martin-Thormeyer E. HIV, cognition and women. *Neuropsychol Rev.* 2009; 19:204–214. [PubMed: 19430907]
- Maruff P, Malone V, McArthur-Jackson C, Mulhall B, Benson E, Currie J. Abnormalities of visual spatial attention in HIV infection and the HIV-associated dementia complex. *J Neuropsychiatry Clin Neurosci.* 1995; 7:325–333. [PubMed: 7580192]
- McArthur JC. HIV dementia: an evolving disease. *J Neuroimmunol.* 2004; 157:3–10. [PubMed: 15579274]
- McArthur JC, Brew BJ. HIV-associated neurocognitive disorders: is there a hidden epidemic? *AIDS.* 2010; 24:1367–1370. [PubMed: 20559041]
- McArthur JC, Steiner J, Sacktor N, Nath A. Human immunodeficiency virus-associated neurocognitive disorders: Mind the gap. *Ann Neurol.* 2010; 67:699–714. [PubMed: 20517932]
- Mishkin M, Appenzeller T. The anatomy of memory. *Sci Am.* 1987; 256:80–89. [PubMed: 3589645]
- Mondadori CR, de Quervain DJ, Buchmann A, Mustovic H, Wollmer MA, Schmidt CF, Boesiger P, Hock C, Nitsch RM, Papassotiropoulos A, Henke K. Better memory and neural efficiency in young apolipoprotein E epsilon4 carriers. *Cereb Cortex.* 2007; 17:1934–47. [PubMed: 17077159]
- Morris R. Developments of a water-maze procedure for studying spatial learning in the rat. *J Neurosci Methods.* 1984; 11:47–60. [PubMed: 6471907]
- Newman MF, Croughwell ND, Blumenthal JA, Lowry E, White WD, Spillane W, Davis RD, Glower DD, Smith LR, Mahanna EP. Predictors of cognitive decline after cardiac operation. *Ann Thorac Surg.* 1995; 59:1326–1330. [PubMed: 7733762]
- Olesen PJ, Schendan HE, Amick MM, Cronin-Golomb A. HIV infection affects parietal-dependent spatial cognition: evidence from mental rotation and hierarchical pattern perception. *Behav Neurosci.* 2007; 121:1163–1173. [PubMed: 18085869]
- Payami H, Zarepari S, Montee KR, Sexton GJ, Kaye JA, Bird TD, Yu CE, Wijsman EM, Heston LL, Litt M, Schellenberg GD. Gender difference in apolipoprotein E-associated risk for familial Alzheimer disease: a possible clue to the higher incidence of Alzheimer disease in women. *Am J Hum Genet.* 1996; 58:803–811. [PubMed: 8644745]
- Piper BJ, Acevedo SF, Craytor MJ, Murray PW, Raber J. The use and validation of the spatial navigation Memory Island test in primary school children. *Behav Brain Res.* 2010; 210:257–262. [PubMed: 20219554]
- Pomara N, Belzer K, Sidtis JJ. Deleterious CNS effects of the APOE epsilon4 allele in individuals with HIV-1 infection may be age-dependent. *Proc Natl Acad Sci U S A.* 2008; 105:E65. author reply E67–68. [PubMed: 18843100]
- Raber J. AR, apoE, and cognitive function. *Horm Behav.* 2008; 53:706–715. [PubMed: 18395206]
- Raber J, Wong D, Yu GQ, Buttini M, Mahley RW, Pitas RE, Mucke L. Apolipoprotein E and cognitive performance. *Nature.* 2000; 404:352–354. [PubMed: 10746713]
- Rackstraw S. HIV-related neurocognitive impairment--a review. *Psychol Health Med.* 2011; 16:548–563. [PubMed: 21745034]
- Ragin AB, Storey P, Cohen BA, Edelman RR, Epstein LG. Disease burden in HIV-associated cognitive impairment: a study of whole-brain imaging measures. *Neurology.* 2004; 63:2293–2297. [PubMed: 15623689]
- Rizk-Jackson A, Robertson J, Raber J. Tfm-AR modulates the effects of ApoE4 on cognition. *J Neurochem.* 2008; 105:63–67. [PubMed: 18039320]
- Rizk-Jackson AM, Acevedo SF, Inman D, Howieson D, Benice TS, Raber J. Effects of sex on object recognition and spatial navigation in humans. *Behav Brain Res.* 2006; 173:181–190. [PubMed: 16887201]

- Rohit M, Levine A, Hinkin C, Abramyan S, Saxton E, Valdes-Sueiras M, Singer E. Education correction using years in school or reading grade-level equivalent? Comparing the accuracy of two methods in diagnosing HIV-associated neurocognitive impairment. *J Int Neuropsychol Soc.* 2007; 13:462–470. [PubMed: 17445295]
- Sa MJ, Madeira MD, Ruela C, Volk B, Mota-Miranda A, Paula-Barbosa MM. Dendritic changes in the hippocampal formation of AIDS patients: a quantitative Golgi study. *Acta Neuropathol.* 2004; 107:97–110. [PubMed: 14605830]
- Sacktor N, McDermott MP, Marder K, Schifitto G, Selnes OA, McArthur JC, Stern Y, Albert S, Palumbo D, Kieburtz K, De Marcaida JA, Cohen B, Epstein L. HIV-associated cognitive impairment before and after the advent of combination therapy. *J Neurovirol.* 2002; 8:136–142. [PubMed: 11935465]
- Sanchez-Alavez M, Criado J, Gomez-Chavarin M, Jimenez-Anguiano A, Navarro L, Diaz-Ruiz O, Galicia O, Sanchez-Narvaez F, Murillo-Rodriguez E, Henriksen SJ, Elder JH, Prospero-Garcia O. HIV-and FIV-derived gp120 alter spatial memory, LTP, and sleep in rats. *Neurobiol Dis.* 2000; 7:384–394. [PubMed: 10964609]
- Schouten J, Cinque P, Gisslen M, Reiss P, Portegies P. HIV-1 infection and cognitive impairment in the cART era: a review. *AIDS.* 2011; 25:561–575. [PubMed: 21160410]
- Selnes OA. Memory loss in persons with HIV/AIDS: assessment and strategies for coping. *AIDS Read.* 2005; 15:289–92. [PubMed: 15962451]
- Shi J, Zhao CB, Vollmer TL, Tyry TM, Kuniyoshi SM. APOE epsilon 4 allele is associated with cognitive impairment in patients with multiple sclerosis. *Neurology.* 2008; 70:185–190. [PubMed: 17460153]
- Tang H, Lu D, Pan R, Qin X, Xiong H, Dong J. Curcumin improves spatial memory impairment induced by human immunodeficiency virus type 1 glycoprotein 120 V3 loop peptide in rats. *Life Sci.* 2009; 85:1–10. [PubMed: 19345695]
- Toro-Nieves DM, Rodriguez Y, Plaud M, Ciborowski P, Duan F, Perez Laspiur J, Wojna V, Melendez LM. Proteomic analyses of monocyte-derived macrophages infected with human immunodeficiency virus type 1 primary isolates from Hispanic women with and without cognitive impairment. *J Neurovirol.* 2009; 15:36–50. [PubMed: 19115125]
- Valcour V, Shikuma C, Shiramizu B, Watters M, Poff P, Selnes O, Holck P, Grove J, Sacktor N. Higher frequency of dementia in older HIV-1 individuals: the Hawaii Aging with HIV-1 Cohort. *Neurology.* 2004a; 63:822–827. [PubMed: 15365130]
- Valcour V, Shikuma C, Shiramizu B, Watters M, Poff P, Selnes OA, Grove J, Liu Y, Abdul-Majid KB, Gartner S, Sacktor N. Age, apolipoprotein E4, and the risk of HIV dementia: the Hawaii Aging with HIV Cohort. *J Neuroimmunol.* 2004b; 157:197–202. [PubMed: 15579298]
- Vance JE, Hayashi H. Formation and function of apolipoprotein E-containing lipoproteins in the nervous system. *Biochim Biophys Acta.* 2010; 1801:806–818. [PubMed: 20170744]
- Velázquez I, Plaud M, Wojna V, Skolasky R, Laspiur JP, Meléndez LM. Antioxidant enzyme dysfunction in monocytes and CSF of Hispanic women with HIV-associated cognitive impairment. *J Neuroimmunol.* 2009; 206:106–111. [PubMed: 19101040]
- Vigorito M, LaShomb AL, Chang SL. Spatial learning and memory in HIV-1 transgenic rats. *J Neuroimmune Pharmacol.* 2007; 2:319–328. [PubMed: 18040850]
- Wenham PR, Price WH, Blandell G. Apolipoprotein E genotyping by one-stage PCR. *Lancet.* 1991; 337:1158–9. [PubMed: 1674030]
- Wiley CA, Soontornniyomkij V, Radhakrishnan L, Masliah E, Mellors J, Hermann SA, Dailey P, Achim CL. Distribution of brain HIV load in AIDS. *Brain Pathol.* 1998; 8:277–284. [PubMed: 9546286]
- Wojna V, Robles L, Skolasky RL, Mayo R, Selnes O, de la Torre T, Maldonado E, Nath A, Melendez LM, Lasalde-Dominicci J. Associations of cigarette smoking with viral immune and cognitive function in human immunodeficiency virus-seropositive women. *J Neurovirol.* 2007a; 13:561–568. [PubMed: 18097887]
- Wojna V, Skolasky RL, Hechavarria R, Mayo R, Selnes O, McArthur JC, Melendez LM, Maldonado E, Zorrilla CD, Garcia H, Kraiselburd E, Nath A. Prevalence of human immunodeficiency virus-

- associated cognitive impairment in a group of Hispanic women at risk for neurological impairment. *J Neurovirol.* 2006; 12:356–364. [PubMed: 17065128]
- Wojna V, Skolasky RL, McArthur JC, Maldonado E, Hechavarria R, Mayo R, Selnes O, Ginebra T, de la Torre T, Garcia H, Kraiselburd E, Melendez-Guerrero LM, Zorrilla CD, Nath A. Spanish Validation of the HIV Dementia Scale in Women. *AIDS Patient Care STDS.* 2007b; 21:930–941. [PubMed: 18154490]
- Xu H, Bae M, Tovar-Romo LB, Patel N, Bandaru VV, Pomerantz D, Steiner JP, Haughey NJ. The human immunodeficiency virus coat protein gp120 promotes forward trafficking and surface clustering of NMDA receptors in membrane microdomains. *J Neurosci.* 2011; 31:17074–17090. [PubMed: 22114277]
- Zink WE, Anderson E, Boyle J, Lynette H, Rodriguez JS, Xiong H, Gendelman HE, Persidsky Y. Impaired spatial cognition and synaptic potentiation in a murine model of human immunodeficiency virus type 1 encephalitis. *J Neurosci.* 2002; 22:2096–2105. [PubMed: 11896149]
- Zola SM, Squire LR, Teng E, Stefanacci L, Buffalo EA, Clark RE. Impaired recognition memory in monkeys after damage limited to the hippocampal region. *J Neurosci.* 2000; 20:451–463. [PubMed: 10627621]

Figure 1.

Differences in MI test performance between HIV-seropositive and seronegative females. **(A)** There was a difference between the HIV-seropositive and seronegative groups in velocity during the visible and hidden trials ($*p < 0.05$). **(B)** There was a difference in latency to target for between HIV status groups during the visible and hidden trials ($*p < 0.05$). Tukey's post-hoc suggests differences between the seronegative and seropositive, impaired group in latency in visible trials ($\#p < 0.05$), but not in hidden trials. **(C)** Differences were also found between the seropositive and seronegative groups in cumulative distance to target for both the visible trials ($*p < 0.05$). In stratified ANOVAs, post-hoc analysis suggested differences are due to reduced performance in seropositive impaired group ($\#p < 0.05$). **(D)** The seronegative subjects had a greater percentage of successful trials (i.e., trials in which they found the target within two minutes) than the seropositive subjects overall ($*p < 0.05$) and the seropositive, impaired ($\#p < 0.05$) group. **(E)** HIV seronegative subjects spent more time in the target quadrant during the probe trial ($+++p < 0.001$, Wilcoxon Sign Rank Test of target quadrant vs. all other quadrants). Overall, seropositive subjects did not display less preference for the target quadrant. When stratified, the seropositive, normal subjects displayed higher preference for the target quadrant compared to other quadrants (75%) with only 63% of the impaired group spending $>51\%$ of time in the target indicating impaired delayed memory performance. Graph was performed using prism program.

Figure 2.

Differences in MI Test Performance between HIV-seropositive $\epsilon 4$ Carriers and Non- $\epsilon 4$ Carriers. (A) No genotype dependent differences were seen for genotype for other HIV status group. (B) Only in the seropositive group did $\epsilon 4$ carriers perform worse than non- $\epsilon 4$ carriers in the visible trials, with difference between the two groups in the hidden trials. (C) In cumulative distance to target during the visible trials there were no significant effects of genotype within HIV status groups. (D) All groups were highly successful in finding the four visible targets within two minutes (% successful trials). However, during the four hidden trials the seropositive $\epsilon 4$ carriers were significantly less successful in finding the target within two minutes compared to non- $\epsilon 4$ carriers ($^{\wedge}p < 0.05$). (E) The seropositive non- $\epsilon 4$ carriers also displayed a preference for the target quadrant ($^{+}p < 0.05$, $^{+++}p < 0.001$, Wilcoxon Sign Rank Test of target vs. all other quadrants). Only the seropositive $\epsilon 4$ carriers failed to display target quadrant preference, indicating impaired delayed memory. Graph was performed using prism program.

Table 1

HIV-1 related proteins effects on spatial learning and memory in rodents.

Model	Effect	References
HIVE/SCID mice	The cognitive deficits manifest as longer latencies to locate the visible platform on the last day of the MWM acquisition period and during a retention test (probe trial) 8 days later. Evidence of impairments in spatial memory in radial water arm maze.	(Griffin <i>et al</i> , 2004; Keblesh <i>et al</i> , 2009; Zink <i>et al</i> , 2002)
Spargue-Dawley rats (HIV-1Tg)	Deficits in modified MWM in latency to platform in hidden trials, but did not show a deficit in their memory of the general location of the hidden platform. Deficits in reversal learning and new strategy learning in modified MWM.	(Lashomb <i>et al</i> , 2009; Vigorito <i>et al</i> , 2007)
Transgenic mice expressing gp120	MWM learning (visible trials) impairments in 3-month-olds. Spatial memory (probe trial) impairments in 12-month-olds.	(D'Hooge <i>et al</i> , 1999)
Wistar rats with ICV infusion of gp120	Results showed that while both HIV- and FIV-derived gp120 impaired the performance in the Barnes maze, only HIV-derived gp120 impaired the induction and maintenance of LTP.	(Sanchez-Alavez <i>et al</i> , 2000)
Doxycycline-inducible transgenic mice expressing HIV-1 Tat ₁₋₈₆ under GFAP	Significantly longer latency and traveled longer distances to find the platform than Tat- mice. No differences in swim speed were observed. The Tat-induced disruption in spatial learning coincided with suppression of LTP in hippocampal.	(Fitting <i>et al</i> , 2008)
Sprague-Dawley rats ICV infusion of gp 120 Wister rates ICV infusion of TAt	The gp120 treated rats are deficit in learning (visible trials) and spatial memory (hidden trials) in MWM. Attenuation of learning in radial arm maze.	(Glowa <i>et al</i> , 1992; Tang <i>et al</i> , 2009) (Li <i>et al</i> , 2004)

gp120 – glycoprotein 120 in HIV-1; Tat - Trans-Activator of Transcription in HIV-1; HIVE – HIV-1 encephalitis; MDM – monocyte-derived macrophages; SCID - Severe combined immunodeficient; MWM - Morris water maze; LTP - long-term potentiation; HIV-1Tg – Noninfectious HIV-1 with gag-pol deletion; ICV – intracerebroventricular; GFAP – glial fibrillary acidic protein

Table 2

HIV-seropositive characteristic

	HIV-seropositive		<i>I_p</i>
	Normal	Impaired	
N	8	12	
Age	39.1 ± 3.0	42.9 ± 3.5	0.41
CSF HIV RNA Viral Load (log) (N)	2.1 ± 0.2 (6)	1.7 ± 0.1 (12)	0.06
Plasma HIV RNA Viral Load (log) (N)	2.8 ± 0.8 (8)	2.0 ± 0.5 (12)	0.10
CD4 nadir (cells/mm ³)	308.9 ± 55.5	482.1 ± 93.8	0.59
CD4 (cells/mm ³)	477.9 ± 43.9	740.6 ± 118.9	0.28
<u>Antiretroviral Treatment (%)</u>			
Naive	2/8 (25%)	2/12 (16.6%)	
ART		1/12 (8.3%)	
cART	6/8 (75%)	9/12 (75%)	
CPE (N)	8.7 ± 0.7 (5)	8.8 ± 0.9 (11)	0.71
Protease Inhibitor (%)	5/6 (83.3%)	6/9 (66.6%)	0.28
ApoE CSF levels (I μ g/mL)	4.9 ± 1.3	5.1 ± 1.2	0.92
HCV (% positive)	1/8 (12.5%)	3/12 (25%)	0.50
Toxicology (% positive)	25%	16.66% (marijuana[1],	0.66
(agent[#patients])	(cocaine[1], marijuana[1])	cocaine/marijuana[1])	

Mean ± SEM, CPE = Central Nervous System penetration effect (Letendre *et al*, 2010), HCV = Hepatitis C virus

ART = single drug antiretroviral treatment, cART = combined antiretroviral treatment

I_p
Students T-test

Table 3

Neurocognitive testing in HIV-seronegative and HIV-seropositive subjects

	HIV status		2 _p	HIV-seropositive		3 _F	3 _p
	Seronegative	Seropositive		Normal	Impaired		
N	16	20		8	12		
Age ^I	41.4 ± 2.3	41.4 ± 2.4	0.99	39.1 ± 2.9	42.9 ± 3.5	0.33	0.72
Education (yr)	13.4 ± 0.6	12.9 ± 0.5	0.49	13.1 ± 1.1	12.7 ± 0.5	0.29	0.74
BDI-II ^I	7.7 ± 2.2	9.8 ± 2.8	0.52	4.5 ± 1.6	13.1 ± 3.3	2.52	0.12
Reading ^I	28.3 ± 0.5	27.5 ± 0.7	0.41	28.9 ± 0.4	26.6 ± 1.2	2.19	0.13
Vocabulary ^I	50.8 ± 3.2	48.1 ± 3.1	0.54	48.3 ± 4.5	47.9 ± 4.4	0.18	0.83
I. NPZ	0.3 ± 0.2	0.2 ± 0.1	0.41	0.6 ± 0.1	-0.1 ± 0.1 ^{4,5}	6.43	0.004
II. Neuropsychological domains/subtests							
1. Frontal Executive	0.1 ± 0.3	0.1 ± 0.2	0.92	0.8 ± 0.1	-0.3 ± 0.2 ⁵	3.61	0.04
a. Stroop Color/Word	0.1 ± 0.4	0.2 ± 0.2	0.70	0.5 ± 0.1	0.1 ± 0.3	0.41	0.67
b. Trail Making B	0.1 ± 0.3	0.0 ± 0.4	0.85	1.0 ± 0.2	-0.6 ± 0.5 ⁴	4.32	0.02
2. Psychomotor Speed	0.2 ± 0.1	-0.1 ± 0.2	0.06	0.2 ± 0.1	-0.4 ± 0.2 ⁴	4.40	0.02
a. Symbol Digit Modality Test	0.4 ± 0.3	-0.2 ± 0.2	0.08	0.3 ± 0.2	-0.5 ± 0.2 ⁴	3.40	0.05
b. Visual RT non-dominant hand	0.1 ± 0.2	-0.1 ± 0.3	0.56	0.4 ± 0.3	-0.3 ± 0.2	1.24	0.30
c. Auditory RT non-dominant hand	0.2 ± 0.2	-0.2 ± 0.2	0.21	-0.0 ± 0.2	-0.3 ± 0.4	1.04	0.37
3. Verbal Memory (RAVLT)	0.2 ± 0.2	0.4 ± 0.1	0.27	0.5 ± 0.3	0.4 ± 0.2	0.73	0.49
a. Trial 5	0.2 ± 0.1	0.2 ± 0.2	0.77	0.3 ± 0.3	0.2 ± 0.2	0.07	0.94
b. Memory Recall	0.3 ± 0.2	0.9 ± 0.2	0.10	0.8 ± 0.4	0.9 ± 0.3	1.39	0.26
c. Delayed Recognition	0.1 ± 0.2	0.2 ± 0.3	0.57	0.5 ± 0.3	0.1 ± 0.2	0.80	0.46

	HIV status		HIV-seropositive		z	p
	Seronegative	Seropositive	Normal	Impaired		
4. Motor Speed						
a. Trail Making A	0.6 ± 0.1	0.2 ± 0.3	0.8 ± 0.1	-0.3 ± 0.4 ^{4,5}	4.63	0.02
	0.1 ± 0.3	-0.2 ± 0.4	0.9 ± 0.2	-0.1 ± 0.6 ⁵	3.88	0.03
b. Grooved Pegboard dominant hand	0.7 ± 0.1	0.4 ± 0.3	0.9 ± 0.2	0.0 ± 0.5	1.79	0.18
c. Grooved Pegboard non-dominant hand	0.1 ± 0.1	0.4 ± 0.3	0.7 ± 0.3	0.2 ± 0.5	1.91	0.16

z -scores Mean ± SEM, BDI-II = Spanish Version Beck Depression Inventory II, NPZ = average of all test z -scores, RAVLT = Rey Auditory Verbal Learning Test, RT = reaction time

¹Raw score ± SEM

²Students T-test between seronegative and seropositive, significant difference p 0.05 in bold

³ANOVA between seronegative, seropositive normal and seropositive impaired p 0.05 in bold

⁴Tukey post-hoc test indicate significant differences p 0.05 between seronegative and seropositive impaired

⁵Tukey post-hoc test indicate significant differences p 0.05 between seropositive normal and seropositive impaired

Table 4

Spearman's Correlations between Memory Island and other Neuropsychological Measures for All Subjects

	Visible Velocity (units/sec)	Visible Latency (sec)	Hidden Latency (sec)
I. NPZ	0.23 (0.17)	-0.49 (0.02)¹	-0.42 (0.01)¹
II. Neuropsychological domains/subtests			
1. Frontal Executive	0.29 (0.08)	-0.29 (0.13)	-0.35 (0.04)
a. Stroop Color/Word	0.21 (0.22)	-0.18 (0.10)	-0.19 (0.37)
b. Trail Making B	0.27 (0.11)	-0.34 (0.05)¹	-0.46 (0.004)²
2. Psychomotor Speed	0.43 (0.008)²	-0.48 (0.003)²	-0.43 (0.009)²
a. Symbol Digit Modality Test	0.35 (0.04)¹	-0.46 (0.006)²	-0.42 (0.01)²
b. Visual RT non-dominant hand	0.24 (0.16)	-0.24 (0.16)	-0.30 (0.08)
c. Auditory RT non-dominant hand	0.14 (0.41)	-0.11 (0.53)	-0.13 (0.46)
3. Verbal Memory (RAVLT)	-0.12 (0.47)	-0.09 (0.57)	-0.281 (0.22)
a. Trial 5	-0.10 (0.54)	-0.07 (0.69)	-0.13 (0.41)
b. Memory Recall	-0.28 (0.10)	-0.13 (0.45)	-0.11 (0.50)
c. Delayed Recognition	0.04 (0.83)	-0.21 (0.21)	-0.27 (0.10)
4. Motor Speed	0.26 (0.13)	-0.36 (0.03)	-0.15 (0.37)
a. Trail Making A	0.25 (0.14)	-0.32 (0.06)	-0.23 (0.16)
b. Grooved Pegboard dominant hand	0.17 (0.32)	-0.25 (0.14)	-0.04 (0.79)
c. Grooved Pegboard non-dominant hand	-0.24 (0.15)	-0.28 (0.09)	-0.10 (0.54)

Correlation Coefficient (*p* value)

NPZ = average of all test z-scores, RAVLT = Rey Auditory Verbal Learning Test, RT = reaction time

¹
p < 0.05²
p < 0.01 statistically significant in bold

Table 5

Effects s4 on Neurocognitive testing in HIV-seronegative and HIV-seropositive subjects

	HIV-seronegative		p	HIV-seropositive		p
	Non-e4	Non-e4		Non-e4	Non-e4	
N	10	6		15	5	
Age	40.0 ± 2.8	43.7 ± 4.3	0.47	39.2 ± 2.7	48.0 ± 3.8	0.10
Education (yr)						
Normal Cognition				40%	40%	
Impaired Cognition				60%	60%	
HIV RNA viral load						
log ₁₀ copies/ml						
CSF (N)				1.9 ± 0.1 (13)	1.7 ± 0.5 (5)	0.32
Plasma (N)				2.4 ± 0.2 (15)	2.0 ± 0.3 (5)	0.40
CD4 nadir (cells/mm ³)				718±100	597 ± 134	0.53
CD4 (cells/mm ³)				457 ± 88	462 ± 149	0.97
Treatment						
% Native (N)				4/14 (28.6%)	0/5	
% ART (N)				1/14 (7.1%)	0/5	
% cART (N)				9/14 (64.3%)	5/5 (100%)	
CPE (N)				7.2 ± 1.0 (11)	10.8 ± 1.4 (5)	0.06
% Protease inhibitor (N)				63.6% (11)	50% (4)	0.70
ApoE CSF levels (ag/mL)				5.1 ± 1.0	4.8 ± 1.9	0.89
Beck Depression Inventory				9.3 ± 2.7	11.2 ± 4.6	0.72
I. NPZ	0.5 ± 0.2	-0.0 ± 0.2	0.05	0.2 ± 0.1	0.1 ± 0.2	0.63
II. Neuropsychological domains/subtests						
1. Frontal Executive	0.5 ± 0.3	-0.6 ± 0.4	0.03	0.0 ± 0.2	0.4 ± 0.4	0.40
a. Stroop Color Word	0.7 ± 0.3	-0.1 ± 0.4	0.02	0.2 ± 0.3	0.4 ± 0.5	0.74
b. Trail Making B	0.4 ± 0.1	-0.3 ± 0.6	0.27	-0.1 ± 0.4	0.4 ± 0.6	0.34
2. Psychomotor Speed	0.2 ± 0.2	0.2 ± 0.3	0.98	-0.0 ± 0.2	-0.5 ± 0.3	0.33
a. Symbol Digit Modality	0.7 ± 0.3	-0.1 ± 0.4	0.19	-0.2 ± 0.2	-0.0 ± 0.4	0.47

	HIV-seronegative		HIV-seropositive		
	Non-e4		Non-e4		p
b. Visual Reaction Time non-dominant hand	0.0 ± 0.3	0.3 ± 0.4	0.2 ± 0.3	-0.7 ± 0.5	0.34
c. Auditory Reaction Time non-dominant hand	-0.0 ± 0.3	0.5 ± 0.3	-0.0 ± 0.2	-0.6 ± 0.4	0.22
3. Verbal Memory (RAVLT)	0.4 ± 0.2	-0.0 ± 0.2	0.4 ± 0.2	0.5 ± 0.3	0.97
a. Trial 5	0.3 ± 0.2	-0.1 ± 0.3	0.1 ± 0.2	0.6 ± 0.3	0.67
b. Memory Recall	0.4 ± 0.2	-0.5 ± 0.3	0.2 ± 0.2	0.4 ± 0.3	0.35
c. Delayed Recognition	0.5 ± 0.3	0.0 ± 0.4	1.0 ± 0.2	0.4 ± 0.4	0.25
4. Motor Speed	0.8 ± 0.3	0.3 ± 0.4	0.3 ± 0.3	-0.1 ± 0.4	0.58
a. Trail Making A	0.5 ± 0.5	-0.5 ± 0.6	0.2 ± 0.4	-1.5 ± 0.7	0.08
b. Grooved Pegboard dominant hand	0.8 ± 0.4	0.4 ± 0.5	0.3 ± 0.3	0.6 ± 0.5	0.67
c. Grooved Pegboard non-dominant hand	0.9 ± 0.3	0.1 ± 0.5	0.3 ± 0.3	0.7 ± 0.5	0.48

Mean ± SEM. Students T-test non-s4 versus s4 carrier, significant difference $p < 0.05$ in bold. ART = single drug antiretroviral treatment, cART = combined antiretroviral treatment.